{"schema_version":"1.0","type":"article","title":"生醫公司 IR 不是把簡報變漂亮，而是把管線變成可追蹤的資本市場故事","url":"https://drugnews.com.tw/articles/2026-06-10-biotech-ir-capital-market-story.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-10-biotech-ir-capital-market-story.md","lang":"zh-Hant","date":"2026-06-10","publish_at":"2026-06-10T10:30:00+08:00","updated_at":"2026-06-10","category":"商業分析系列","topic":"IR 與資本市場","tags":["IR","資本市場故事","公開資訊","投資人溝通"],"summary":"好的 IR 內容不是宣傳話術，而是把臨床、CMC、監管、商業化與對標公司轉成投資人可以追蹤的節點。","key_points":[],"facts":[],"sections":["投資人不缺資訊，缺的是可採用的結構","一個好的 IR 內容應該回答四件事","合規邊界很重要"],"references":[],"images":[{"alt":"生醫 IR 溝通流程：公開資訊、科學轉譯、資本市場故事、後續追蹤","url":"https://drugnews.com.tw/assets/articles/biotech-ir-capital-market-story/ir-flow.svg"}],"cover_image":"https://drugnews.com.tw/assets/articles/biotech-ir-capital-market-story/ir-flow.svg","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-10）。生醫公司 IR 不是把簡報變漂亮，而是把管線變成可追蹤的資本市場故事。https://drugnews.com.tw/articles/2026-06-10-biotech-ir-capital-market-story.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-06-10-biotech-ir-capital-market-story-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}